Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand has announced that the US Patent and Trademark Office has provided notice that it will award the company US patent for skeletal muscle relaxant on June 17, 2008.
Subscribe to our email newsletter
The company will also be awarded a patent term adjustment of an additional 470 days, providing Eurand with coverage on Amrix until at least February 26, 2025.
Eurand’s patent will include claims covering Amrix (cyclobenzaprine hydrochloride), a product currently marketed in the US by Cephalon, under license from Eurand. Amrix is said to be the only approved once-daily formulation of the skeletal muscle relaxant, cyclobenzaprine hydrochloride, for the relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Gearoid Faherty, CEO of Eurand, said: “This newly issued patent will be particularly meaningful given Cephalon’s commitment to the product and its success thus far in the US marketplace.”